Because there is such a wide variation of symptoms, diagnosis can be difficult. On average, diagnosis for each patient takes six to 10 years. Some of the most common symptoms of celiac disease include: Gas and bloating Mood swings and fatigue Joint pain Some people with celiac disease exhibit no symptoms at all and are completely in the dark about their diagnosis. Many take this to mean that if there are no symptoms, then there isn’t a problem, but that simply isnt true. Celiac disease, if left untreated, can cause a myriad of serious life threatening problems because of its nature as an autoimmune disorder. Patients with celiac disease who do not follow a gluten-free diet often suffer from malnutrition. In children, this can cause stunted growth, delayed development, and behavioral issues. For women, untreated celiac disease can lead to infertility and miscarriage, as well as other reproductive issues because of the malabsorption of calcium and vitamin D. Celiac disease can cause bone weakness and nerve damage, causing constant pain. Most unnerving, people with untreated celiac disease have a significantly greater risk of developing several forms of cancer, including lymphoma and small bowel cancer. Diagnosis and treatment Because the symptoms of celiac disease can mimic other diseases like irritable bowel syndrome and Crohns disease , the best way to diagnose celiac disease is to start with a blood test. Currently, doctors test for total IgA, IgA-tTG, IgA-EMA, and possibly IgG/IgA-DGP or IgG-AGA. Its important that the patient continue to consume gluten before the blood tests to properly measure the immune systems response to that diet. If the blood tests come back positive, the doctor will likely do a biopsy of the small intestine via endoscopy to confirm the diagnosis. The earlier the disease is diagnosed, the easier it is for your body to heal the damage.

my company

Most People with Celiac Disease Open to Pharmaceutical Treatments

Image: Wikimedia Commons

It occurs in genetically predisposed individuals and is caused by an immunological reaction to gluten, found in wheat, barley and rye. Estimates suggest that 1% of the world’s population is affected by celiac disease, and prevalence is expected to increase dramatically with improved diagnosis and awareness of the disease.The celiac market is projected to reach $8 billion by 2019. There are currently no treatments approved for celiac disease and the only treatment option is a life-long, strict, gluten-free diet, which is difficult to maintain both due to food contamination with gluten, as well as eating habits in a social setting. About BioLineRx BioLineRx is a publicly-traded, clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates. The Company in-licenses novel compounds primarily from academic institutions and biotech companies based in Israel, develops them through pre-clinical and/or clinical stages, and then partners with pharmaceutical companies for advanced clinical development and/or commercialization. BioLineRx’s current portfolio consists of a variety of clinical and pre-clinical projects, including: BL-1040 for prevention of pathological cardiac remodeling following a myocardial infarction, which has been out-licensed to Ikaria Inc. and is in the midst of a pivotal CE-Mark registration trial; BL-5010 for non-surgical removal of skin lesions, which is expected to commence a pivotal CE-mark registration trial in early 2014; BL-8040 for treating acute myeloid leukemia (AML) and other hematological indications, which is in the midst of a Phase 2 study; and BL-7010 for celiac disease, which recently commenced a Phase 1/2 study. For more information on BioLineRx, please visit or download the investor relations mobile device app, which allows users access to the Company’s SEC documents, press releases, and events. BioLineRx’s IR app is available on the iTunes App Store as well as the Google Play Store. Various statements in this release concerning BioLineRx’s future expectations, including specifically those related to the development and commercialization of BL-7010, constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include words such as “may,” “expects,” “anticipates,” “believes,” and “intends,” and describe opinions about future events. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of BioLineRx to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Some of these risks are: changes in relationships with collaborators; the impact of competitive products and technological changes; risks relating to the development of new products; and the ability to implement technological improvements. These and other factors are more fully discussed in the “Risk Factors” section of BioLineRx’s most recent annual report on Form 20-F filed with the Securities and Exchange Commission on March 12, 2013.

her comment is here

BioLineRx Enters Clinic with Novel Treatment for Celiac Disease

Pope Draws 6.6 Million to Vatican in 2013

Ads by Google: 10/17/2013 – A gluten-free diet is till the only treatment for celiac disease, but a number of companies are working on pharmaceutical treatments. However, very little information exists bout the level of interest among patients in using a medication to treat celiac disease. A research team set out to assess interest levels among patients in medical treatments for celiac disease. The research team included Christina A. Tennyson, Suzanne Simpson, Benjamin Lebwohl, Suzanne Lewis and Peter H. R. Green. For their study, the researchers submitted a questionnaire to celiac disease patients and collected data on demographics, presentation, and interest in medication. The questionnaire included three validated celiac disease-specific instruments: Celiac Disease Associated Quality of Life, the Celiac Symptom Index, and the Celiac Dietary Adherence Test. The team received 365 responses from people with biopsy -proven celiac disease. A total of 276 women and 170 men over 50 years of age responded to the study. Of these respondents, 154 experienced classic, diarrhea predominant celiac disease. In all 339 people responded to the question asking if they were interested in using a medication to treat celiac disease, 66% of whom indicated that they were interested. The questionnaire responses broke down as follows: Older people showed the greatest interest, with 71% of people over 50 years of age saying they were interested, compared with 60% of people under 50 years of age, (p = 0.0415).

no title